An anonymous reader shares a report: In deciding on cancer treatment, doctors often get together in a “tumor board” to go over the options. IBM’s Watson now sits in on those meetings in a few hospitals, such as in South Korea and India — and it generally makes the same calls that a human expert would. So says IBM in a series of studies it’s presenting this weekend at the ASCO cancer treatment conference in Chicago. “It’s not making a diagnosis. That’s not what we set out to do,” says Andrew Norden of IBM’s Watson Health division. “They will run Watson Oncology in a tumor board and sort of get another external opinion.” Watson’s “concordance rate” — the degree to which it agrees with human doctors — ranged from 73% to 96%, depending on the type of cancer (such as colon cancer) and the particular hospital where the study was done (in India, South Korea, and Thailand).
Read more of this story at Slashdot.